On this page
HCET Home > On-line Training > RVIPP Self Study Manual: Chlamydia
 |
RVIPP Self Study Manual: Chlamydia An HCET LearningLink On-line Training Module Developed by the Region V Infertility Prevention Training Committee, through the generosity of the Gund Foundation. June 2006 |
- 2.0 Nursing Contact Hours are available for this activity
- 2.0 Continuing Education Contact Hours (CECH) for certified health education specialists (CHES) are available for this training activity
Contents
Start here
Introduction
Sections
- Chlamydia Medical Overview
- Guidelines for Screening & Specimen Collection
- Laboratory
- Case Studies
- Diagnosis and Treatment of Chlamydia
- Data
- Client Education & Counseling
- Quality Assurance
- Glossary
- Educational Resources & References
- Post-test
- Evaluation
Introduction
The purpose of this manual is to provide clinic staff at the Infertility Prevention Sites with a self study
guide to familiarize them with the procedures of the Region V Infertility Prevention Project (RVIPP).
The guide should be read and reviewed by all new clinic staff. The manual will provide information
regarding the testing, treatment, and counseling of clients for the infection, Chlamydia trachomatis
(CT). Supervisory oversight should occur as the new staff person reads each module. This self study
manual can also be used by any health care provider outside of the project who is interested in learning
more about testing, treatment, and counseling clients for genital infections.
Health Care Education & Training, Inc.
9640 N. Augusta Drive,
Suite 421
Carmel, IN 46032
Course Description
This self study manual is designed to provide information on the history and purpose of the Infertility Prevention Project, a medical overview of Chlamydia trachomatis (CT) infection, screening and treatment guidelines, client education and counseling guidelines, laboratory technologies used in the diagnosis of CT, and quality assurance practices.
Objectives
Upon completion of this course the reader should be able to:
- Identify the components of a quality assurance programs for Chlamydia trachomatis (CT) screening in the clinic setting.
- Discuss the epidemiology and pathogenesis of CT.
- Identify the clinical presentation and diagnosis of CT genital infections in men and women.
- Describe the recommended screening criteria.
- Describe correct specimen collection techniques and common problems of specimen collection and handling.
- Discuss the basic principles, utility and interpretation of commonly used laboratory tests for the diagnosis of CT infection and common reasons for specimen rejection.
- Describe treatment recommendations and appropriate regimens for CT based on patient profile.
- List elements and processes of data collection and reporting activities.
- Identify essential information that must be presented to the client regarding partner referral and behavior change strategies.
- 2 nursing contact hours are available for this activity. To receive a certificate of completion for contact hours, you must submit the completed post test and evaluation to Health Care Education and Training, Inc.
- 2 Certified Health Education Specialist (CHES) Continuing Education Contact Hours (CECH) are available for this activity. To receive a certificate of completion for contact hours, you must submit the completed post test and evaluation to Health Care Education and Training, Inc.
History & Organization of the RVIPP
What is the infertility prevention project?
In 1993 Congress appropriated funds to the Centers for Disease Control and Prevention (CDC) to begin a national STD-related Infertility Prevention Program. The program was designed to improve screening, surveillance and treatment of the infection, Chlamydia trachomatis (CT), in the United States. By 1996 the CDC had contracted with all states for demonstration level health funding to provide tests/treatment for chlamydia in selected family planning and sexually transmitted disease clinics. Approximately 75% of infected women and 50% of infected men have no symptoms of CT, and therefore, may not seek health care until severe health problems occur. When diagnosed CT can be easily treated and cured. Untreated CT can cause severe and costly reproductive and health problems including pelvic inflammatory disease (PID), which frequently results in chronic pelvic pain and is linked to infertility and ectopic pregnancy. CT is one of the major causes of tubal infertility in the United States.1Who is involved in the Region V Infertility Prevention Project?
The six states in Region V, Illinois, Indiana, Michigan, Minnesota, Ohio, and Wisconsin, have been working collaboratively since 1995 through the RVIPP Advisory Committee. Thirty members from the six states worked jointly to develop screening criteria, collect data, establish volume purchasing, exchange information and research, and set regional objectives. The members represent the fields of family planning, STD, maternal and child health, public health laboratories, and epidemiology. Each state has an infertility prevention state alliance that relays recommendations to the RVIPP Advisory Committee and in turn, receives guidance from the RVIPP. Regional activities are coordinated through Health Care Education and Training, Inc. (HCET), a non-profit organization that provides training, technical assistance, and infrastructure development on issues of women’s health within the region.
What are the health care costs of untreated chlamydia?
According to the Alan Guttmacher Institute in 2002, the population of Region V consisted of 11,581,600 women of childbearing age with 6,091,910 of these women in need of contraceptive services and supplies. Childbearing age is defined here as 13-44 years of age and need is defined as a person living at or below 100% of the poverty level.2
There were 177,069 cases of CT reported in 2004 in Region V and 929,462 reported nationally.3 Up to 40% of women with untreated CT infection will develop PID.1 CDC estimates the health care costs of untreated chlamydia to be more than $2 billion annually in the United States, while screening and treatment programs cost $175 million annually. That means that every dollar spent toward screening and treatment will save $12 in complications that result from untreated CT.4| Aurea Booncharoen Michigan Department of Community Health Washington Square Building, 3rd Floor 109 West Michigan Avenue Lansing, MI 48913 |
Ed Renier Illinois Department of Public Health STD Program, Room 500 525 West Jefferson Springfield, IL 62761 |
| James Greenshields Ohio Department of Health STD Program 161 South High Street, Suite 400 Akron, Ohio 44308-1616 |
Debbie Tripp Cincinnati STD/HIV Prevention Training Center 3101 Burnett Avenue Cincinnati, OH 45229 |
| Candy Hadsall Minnesota Department of Health STD Program P.O. Box 64975 625 Robert Street North St. Paul, MN 55164 |
Loriann S. Wunder, Chair Wisconsin Div. of Public Health STD Control Section 1 W. Wilson St. Rm 318 Madison, WI 53701-2659 |
| Lilly Irvin-Vitela Health Care Education and Training, Inc. 6441 Enterprise Lane, Suite 110 Madison, WI 53719 |
|
Contributors & Editors
| Joyce Alley, RNC | Kris Judd | Richard Steece, PhD |
| Laurie Anderson | Romina Kee, MD | Lydia Steinseifer |
| Aurea Booncharoen, BSN | Bobbie McDonald | Geof Swain, MD |
| Tami Chrestoff | Randi Miller, RNC | Debbie Tripp |
| Norma Denbrook | Steve Moore | Kara Wools, MD |
| Roberta Fisher, RNC | Rosanne Reames, BSN | Wendy Wise |
| James Greenshields | Ed Renier | Loriann Wunder |
| Candy Hadsall, RN | Charlotte Robertson, RNC | Charles Heaton, MD |
| William Schneider |
